These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21945955)
1. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955 [TBL] [Abstract][Full Text] [Related]
2. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889 [TBL] [Abstract][Full Text] [Related]
3. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Yamaguchi H; Shimizu M; Ban S; Koyama I; Hatori T; Fujita I; Yamamoto M; Kawamura S; Kobayashi M; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Ebihara Y; Koike N; Furukawa T Am J Surg Pathol; 2009 Aug; 33(8):1164-72. PubMed ID: 19440145 [TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558 [TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757 [TBL] [Abstract][Full Text] [Related]
6. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919 [TBL] [Abstract][Full Text] [Related]
7. Intraductal tubular adenomas (pyloric gland-type) of the pancreas: clinicopathologic features are similar to gastric-type intraductal papillary mucinous neoplasms and different from intraductal tubulopapillary neoplasms. Chang X; Jiang Y; Li J; Chen J Diagn Pathol; 2014 Sep; 9():172. PubMed ID: 25245835 [TBL] [Abstract][Full Text] [Related]
8. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586 [TBL] [Abstract][Full Text] [Related]
10. Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms. Xiao HD; Yamaguchi H; Dias-Santagata D; Kuboki Y; Akhavanfard S; Hatori T; Yamamoto M; Shiratori K; Kobayashi M; Shimizu M; Fernandez-Del Castillo C; Mino-Kenudson M; Furukawa T J Pathol; 2011 Aug; 224(4):508-16. PubMed ID: 21547907 [TBL] [Abstract][Full Text] [Related]
11. A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm? Muraki T; Uehara T; Sano K; Oota H; Yoshizawa A; Asaka S; Tateishi A; Otsuki T; Shingu K; Matoba H; Kobayashi S; Ichimata S; Watanabe T; Itou T; Tanaka E Pathol Res Pract; 2015 Dec; 211(12):1034-9. PubMed ID: 26586167 [TBL] [Abstract][Full Text] [Related]
12. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis. Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484 [TBL] [Abstract][Full Text] [Related]
13. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice. Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451 [TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Garcia-Carracedo D; Chen ZM; Qiu W; Huang AS; Tang SM; Hruban RH; Su GH Pancreas; 2014 Mar; 43(2):245-9. PubMed ID: 24518503 [TBL] [Abstract][Full Text] [Related]
16. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers. Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266 [TBL] [Abstract][Full Text] [Related]
17. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847 [TBL] [Abstract][Full Text] [Related]
18. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194 [TBL] [Abstract][Full Text] [Related]
19. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Schönleben F; Qiu W; Remotti HE; Hohenberger W; Su GH Langenbecks Arch Surg; 2008 May; 393(3):289-96. PubMed ID: 18343945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]